Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

UDP-glucuronosyltransferase promoter polymorphism in Iranian neonates with idiopathic hyperbilirubinemia

Mahbod Kaveh1, Tahereh Esmailnia, Fatemeh Nayeri

  • 1Department of Neonatology, Bahrami Children Hospital, Tehran University of Medical Sciences, Tehran, Iran. pedkaveh2000@yahoo.com.

Acta Medica Iranica
|January 7, 2014
PubMed

Insights

Certain UGT1A1 gene variants (TA6/7 and TA7/7) are linked to higher serum total bilirubin (STB) levels in Iranian neonates with idiopathic hyperbilirubinemia. These findings suggest genetic factors play a role in neonatal jaundice.

Area of Science:

  • Genetics
  • Neonatology
  • Biochemistry

Background:

  • Idiopathic hyperbilirubinemia is a common condition in neonates.
  • The UGT1A1 gene plays a crucial role in bilirubin metabolism.
  • Genetic variations in the UGT1A1 gene promoter may influence bilirubin levels.

Purpose of the Study:

  • To investigate the association between UGT1A1 gene polymorphisms and idiopathic hyperbilirubinemia in Iranian neonates.
  • To determine if specific genotypes correlate with elevated serum total bilirubin (STB) levels.

Main Methods:

  • A case-control study involving 100 neonates (50 with STB >15mg/dl, 50 with STB <15mg/dl).
  • Polymerase chain reaction (PCR) DNA sequencing was used to analyze thymine-adenine (TA) repeats in the UGT1A1 gene promoter region.
  • Demographic characteristics and STB levels were compared between groups.

Main Results:

  • No significant demographic differences were observed between case and control groups.
  • The TA6/7 and TA7/7 genotypes were found more frequently in neonates with idiopathic hyperbilirubinemia (P<0.001).
  • Significantly higher STB levels were associated with TA6/7 and TA7/7 genotypes (P<0.001).

Conclusions:

  • UGT1A1 gene polymorphisms, specifically TA6/7 and TA7/7 genotypes, are associated with idiopathic hyperbilirubinemia in Iranian neonates.
  • These genetic variations may contribute to elevated bilirubin levels, necessitating consideration in clinical evaluation.
  • Further research into genetic predispositions for neonatal hyperbilirubinemia is warranted.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

7.3K
qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes07:58

qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes

Published on: March 6, 2019

10.3K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
35
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K